As Coronavirus Spreads, a Biotech IPO Squeaks Through. Others May 'Wait and See'

Biopharma Dive

"Biotech companies seeking to go public in the US face a stiff test during the surging outbreak of the new coronavirus, which is dragging down the stock market as the risks to the broader economy become real."

Read the full article

Related Contacts
Charlie Kim Partner, San Diego